Physician profile
Dan G Halpern
NPI 1720273253
$11,550.57
in general payments reported to CMS, 2019-2025
14 companies · $498 in 2025
The $498 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $24.00 · 2022: $8,407 · 2023: $140 · 2024: $2,481 · 2025: $498.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $2,125 · Food and Beverage: $995.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $2,125.00 |
| Food and Beverage | $994.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $10,570.90 | 2022-2025 | Harmony, Avalus |
| Shockwave Medical, INC | $239.93 | 2025 | |
| Edwards Lifesciences Corporation | $150.00 | 2024 | |
| Novartis Pharmaceuticals Corporation | $119.59 | 2020-2025 | |
| Eko Health, INC. | $116.92 | 2024 | |
| Philips North America LLC | $77.47 | 2022-2025 | Extended Holter |
| Janssen Pharmaceuticals, INC | $76.54 | 2023-2024 | Xarelto |
| Novo Nordisk INC | $48.75 | 2025 | Wegovy |
| Actelion Pharmaceuticals US, INC. | $29.16 | 2023 | Opsumit, Uptravi |
| Genzyme Corporation | $27.20 | 2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $24.56 | 2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $24.11 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $23.46 | 2023 | Jardiance |
| Amgen INC. | $21.98 | 2024 | Repatha |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dan Halpern listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.